Senolysis and Seizure Outcomes
Can senolytic drugs reduce seizure severity across distinct epilepsy settings, including when treatment begins after seizures develop?
The bounded research links senolytic treatment to reduced seizures in mTOR-related epilepsy and to reduced seizure severity and improved survival after preventive treatment in aged mice. Following this cluster could clarify how broadly those benefits extend.
Where it stands now
Main bottleneck
The two reports address different epilepsy settings and treatment circumstances, leaving the durability, safety, and applicability of the benefits after seizure onset unresolved.
Watch next
Controlled follow-up evidence testing whether senolytic treatment begun after seizure onset produces sustained seizure reductions, with explicit safety assessment.
Progress timeline
How the evidence has changed over time.
2024 · 2 updates
- Could targeting abnormal brain cells reduce seizures in mice?Research note 1 of 2 · Source date 2024-05-06
- Can clearing senescent cells change how an aging mouse brain handles seizures?Research note 2 of 2 · Source date 2024-06-20
Since the previous research note · Earlier expectation not tested
Track continuity
Since the previous research note: Could targeting abnormal brain cells reduce seizures in mice?
Previous expectation: Selectively removing pathological cells might eventually help children with focal cortical dysplasia control seizures while reducing the need for extensive brain surgery.
What this study adds: This study examined systemic senolytic pretreatment in aged mice facing chemically induced status epilepticus and found reduced acute seizure severity and improved survival. It did not test focal-lesion targeting, pediatric disease or an alternative to surgery.
Current research note
How this Track works
This page changes as new evidence arrives. Open any update to see what researchers found at that point in the story.